Indian Journal of Clinical and Experimental Ophthalmology

Print ISSN: 2395-1443

Online ISSN: 2395-1451

CODEN : IJCEKF

Indian Journal of Clinical and Experimental Ophthalmology (IJCEO) is open access, a peer-reviewed medical journal, published quarterly, online, and in print, by the Innovative Education and Scientific Research Foundation (IESRF) since 2015. To fulfill our aim of rapid dissemination of knowledge, we publish articles ‘Ahead of Print’ on acceptance. In addition, the journal allows free access (Open Access) of its content, which is likely to attract more readers and citations of articles more...


  • Article highlights
  • Article tables
  • Article images

Article statistics

Viewed: 41

PDF Downloaded: 25


Gowda and Kumar L: Comparison of efficacy of topical alcaftadine (0.25%) versus olopatadine (0.1%) in allergic conjunctivitis


Introduction

Allergic conjunctivitis is one of the most common atopic ocular conditions encountered in clinical practice. Early phase reactions of allergic conjunctivitis are mediated majorly by Histamine.1 Human conjunctiva is rich in Mast cells which play vital role in pathogenesis of allergic conjunctivitis.2, 3 Degranulation of mast cells occur in conjunctiva of susceptible individuals following exposure to allergens leading to cross linking of pairs of Ig-E and release of inflammatory mediators like leukotrienes, tryptase, histamine, cytokines and PAF.2

Allergic tissues showed five times over expressions of H4 receptors followed by H1 and H2 receptors as demonstrated by semi-quantitative RT-PCR. A Primary treatment for allergic conjunctivitis being topical antihistamines, Alcaftadine has broad-spectrum action on H1, H2 and H4 receptor and also has immune modulation action on cell recruitment and stabilizes the mast cell.4 Olopatadine hydrochloride is a dual-acting drug with selective H1 receptor antagonistic action and mast cell stabilization action.5

Materials and Methods

A prospective, randomized, open label, parallel group, comparative study was conducted in Bangalore at a tertiary care centre. Institutional ethical committee approval was obtained for the study. 60 consecutive patients of bilateral allergic conjunctivitis (30 in group A and 30 in group B) attending OPD and willing to participate after signed informed consent were enrolled. Exclusion criteria was patients on topical / oral corticosteroids within 2 weeks of enrollment, on lubricants, dry eye disease, past contact lens wearers, ocular surgeries, previous herpes infection, bacterial or viral conjunctivitis, severe allergic conjunctivitis like atopic keratoconjunctivitis, vernal keratoconjunctivitis, pregnant & lactating women, subjects already taking the study drugs and known hypersensitivity to it.

Allergic conjunctivitis subjects were selected and randomized into 2 groups of 30 each by simple random sampling into Group- A and Group- B. Patients in Group - A received topical Alcaftadine 0.25% 1 drop to each eye twice daily and patients in Group-B received topical Olopatadine Hydrochloride 0.1% 1 drop to each eye twice daily for 2 weeks in both the group. Detailed history and clinical examination – slit lamp examination were performed and documented in a prescribed format in each visit. For uniform grading of symptoms and signs at each visit, we used scoring scales from 0-3 (0-Absent, 1- mild, 2-moderate, 3- severe).6 30 subjects per group was the sample size. Statistical Package for the Social Sciences (SPSS) version 11.5 and Microsoft excel were used to analyse the data. Mean and SD for analysing descriptive data and Paired sample T Test for analyzing of significance. Two tailed P values at a significance level of 0.05.

Table 1

Scoring of signs and symptoms of allergic conjunctivitis.6

Signs & Symptoms

Scoring of Signs and Symptoms of Allergic Conjunctivitis

Scoring

0-Absent

1-Mild

2-Moderate

3-Severe

Itching

Absent

Occasional itching without tendency to rub eyes

Frequent itching with tendency to rub eyes

Continuous itching, frequently rubbing eyes

Hyperaemia

Absent

Slightly dilated blood vessels, pink

More Apparent vessel dilatation, more intense color

Numerous and obvious dilated vessels, color deep red

Photophobia

Absent

Occasional

Continuously Photophobic

Eye responds with blepharospas m on exposure to light

Tearing

Absent

Occasional no complaints of discomfort

Frequent, feeling of discomfort

Persistant accompanied by swabbing of eyes

Results

Age distribution of patients in our study (Figure 1), there were higher number of patients between the age group of 21 to 24 years than in age group above 28 years. 66.66% of our study groups were males and 33.33% were females (Figure 2). 63.33% of the study population was from the urban areas and 36.66% were from the rural areas.

Figure 1

Age distribution in the study population

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/ac6cb834-a5b7-4d38-9425-a32e7a24a200/image/ba7e26ef-9c40-4094-9018-c9ff9c110968-uimage.png

Figure 2

Gender distribution in the study population

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/ac6cb834-a5b7-4d38-9425-a32e7a24a200/image/3b76824e-2dd1-4dfa-bd22-564acf21d548-uimage.png

Figure 3

Distribution of residence in the study population

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/ac6cb834-a5b7-4d38-9425-a32e7a24a200/image/c4dc1682-6e70-445a-92cf-8be41b5c0973-uimage.png

Figure 4

Itching scores in the study population

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/ac6cb834-a5b7-4d38-9425-a32e7a24a200/image/48e051ad-6f15-476b-b50b-82f9fca82faf-uimage.png

Figure 5

Hyperaemia scores in the study population

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/ac6cb834-a5b7-4d38-9425-a32e7a24a200/image/178b9199-dbb7-4d07-aef8-b6896a125266-uimage.png

Figure 6

Photophobia scores in the study population

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/ac6cb834-a5b7-4d38-9425-a32e7a24a200/image/b9c46e93-b0cc-4446-a0ac-5cbcedb62bef-uimage.png

Figure 7

Tearing scores in the study population

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/ac6cb834-a5b7-4d38-9425-a32e7a24a200/image/11c79ea0-c835-4bd8-9f8e-f71c4d84902e-uimage.png

Table 2

Statistical table for the signs and symptoms on Day 0, 7 & 14 in the study population

Symptom

Days

Group-A

Group-B

P value

MEAN

SD

MEAN

SD

(<0.05-Statistically Significant)

Itching

D0

2.73

0.583

2.73

0.521

0.54

D7

1.93

0.828

1.97

0.928

0.54

D14

0.23

0.430

0.67

0.711

0.008

Tearing

D0

1.13

0.346

1.03

1.159

0.01

D7

0.13

0.346

0.23

0.430

0.24

D14

0.07

0.254

0.10

0.305

0.3

Hyperaemia

D0

2.87

0.346

2.70

0.596

0.004

D7

2.67

0.479

2.63

0.615

0.184

D14

0.23

0.430

1.10

0.885

0.002

Photophobia

D0

0.67

0.959

0.80

0.997

0.83

D7

0.43

0.817

0.53

0.900

0.60

D14

0.00

0.00

0.007

0.254

Itching scores in Group A receiving alcaftadine 0.25%, the Mean and SD on day 14 for Itching was 0.23 and 0.430 versus 0.67 and 0.711 in Group B receiving olopatadine hydrochloride 0.1% (p-0.008 statistically significant). (Figure 4) hyperaemia scores in Group A receiving alcaftadine 0.25%, the Mean and SD on day 14 for hyperaemia was 0.23 and 0.430 versus 1.10 and 0.885 in Group B receiving olopatadine hydrochloride 0.1% (p-0.002 statistically significant). (Figure 5)

In case of Photophobia the study groups could not be compared as all study subjects were symptom free in Group A, hence we could not arrive at the statistical Significance. For tearing, Group A Receiving Alcaftadine 0.25% the Mean and SD on day 14 for Tearing was 0.07 and 0.254 Versus 0.10 and 0.305 in Group B receiving Olopatadine Hydrochloride 0.1% (p-0.3 not statistically significant).

Discussion

We conducted a prospective, randomized, open label, parallel group, comparative study to find out whether topical Alcaftadine is more effective than olopatadine 0.1% eye drop for managing allergic conjunctivitis. The aim of the study is to improve the quality of life by reducing the signs and symptoms effectively. Analysis of Data from 60 patients (30 in group A and 30 in group B)for overall efficacy in reducing the signs and symptoms of allergic conjunctivitis at 2weeks after instillation, we found that Alcaftadine 0.25% efficacy was statistically significantly higher compared to olopatadine 0.1% eye drops.

In another comparative study which enrolled 285 subjects following conjunctival allergen challenge test it was noted that the mean itch score was lower at 3,5and 7 minute in Alcaftadine group when compared to olopatadine group.7

Another study test in mice showed Alcaftadine treated animals had reduced conjunctival eosinophil infiltration.8

Alcaftadine displays other therapeutic properties such as ability to reduce conjunctival eosinophil recruitment and a protective effect on epithelial tight junction protein expression.8

Primary outcome was that Alcaftadine 0.25% is more effective in treating itching, hyperemia and photophobia than 0.1% olopatadine hydrochloride.

Secondary outcome was that patients were comfortable with Alcaftadine 0.25% during the study and showed good response after 2 weeks of study than 0.1% olopatadine hydrochloride.

Literature reviews shows that Alcaftadine 0.25% is more effective and safer than 0.1% olopatadine hydrochloride.

No adverse effect noted in patients during the study period in both the groups.

Strengths of the Study

We have selected a newer generation antihistaminic which can play predominant role in reducing allergic conjunctivitis.

Conclusion

Reduction of signs and symptoms of allergic conjunctivitis at 2 weeks from baseline was noted in both the groups but Alcaftadine 0.25% group showed more significantly effective reduction.

Limitations

Fewer study subjects, different ethnic groups not included.

Source of Funding

None.

Conflict of Interest

The authors declare no conflict of interest.

References

1 

MB Abelson MRA Smith Histamine and the eyeImmunology and immunopathology of the eyeMasson PublishingNew York19793624

2 

MRA Smith JV Greiner RS Baird Number of inflammatory cells in the normal conjunctivaAm J Ophthalmol19788622509

3 

RP Maurya VP Maurya MK Singh P Bhushan Ocular Allergy: An OverviewRespiratory Disease & Allergy First editionTara Book VaranasiIndia2012569-82

4 

R Namdar C Valdez Alcaftadine: a topical antihistamine for use in allergic conjunctivitisDrugs Today (Barc)201147128839010.1358/dot.2011.47.12.1709243

5 

E Uchio Treatment of allergic conjunctivitis with olopatadine hydrochloride eye dropsClin Ophthalmol20082352531

6 

SJ Sarker AN Chowdhury Z Hussain AM Hossain H Chowdhury Comparison of the therapeutic efficacy of 0.1% olopatadine hydrochloride and 0.025% ketotifen fumarate in allergic conjunctivitisClin Pract2011854553

7 

EB Mclaurin NP Marsico JB Ciolino L Villanueva JM Williams DA Hollander Alcaftadine 0.25% versus olopatadine 0.2% in prevention of ocular itching in allergic conjunctivitisJ Allergy ClinImmunol2014133278

8 

KJ Lane SJ Ono Comparison of Alcaftadine and Olopatadine Effects on Ocular Epithelium and Eosinophil Recruitment in a Murine Model of Allergic ConjunctivitisInvest Ophthalmol Vis Sci201152146417



jats-html.xsl

© This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Article type

Original Article


Article page

630-633


Authors Details

M S Smitha Gowda, Kiran Kumar L*


Article History

Received : 03-02-2020

Accepted : 28-06-2021

Available online : 03-01-2022


Article Metrics


View Article As

 


Downlaod Files

   








Open Abstract (Increase article citation) Wiki in hindi